These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 29974949

  • 41. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
    Link-Lenczowska D, Sacha T, Zawada M, Czekalska S, Florek I, Skotnicki AB.
    Przegl Lek; 2014; 71(5):258-62. PubMed ID: 25248240
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.
    Int J Mol Sci; 2019 May 06; 20(9):. PubMed ID: 31064152
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
    Sazawal S, Chikkara S, Singh K, Chaubey R, Chandra D, Mishra P, Mahapatra M, Seth T, Saxena R.
    Ann Diagn Pathol; 2017 Apr 06; 27():24-27. PubMed ID: 28325357
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
    Pavlovsky C, Giere I, Moiraghi B, Pavlovsky MA, Aranguren PN, García J, Fernandez I, Bengió R, Milone J, Labanca V, Uriarte R, Lombardi V, Reinoso FG, Magariños AE, Martinez L, Murro H, Lastiri F, Pavlovsky S.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 06; 11(3):280-5. PubMed ID: 21658656
    [Abstract] [Full Text] [Related]

  • 51. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY, Wang MC, Lin TL, Lan YJ, Chen CC, Yang Y, Hsiao PC, Lai CL, Chang CH, Lin TH.
    Leuk Res; 2013 Jan 06; 37(1):43-9. PubMed ID: 23062378
    [Abstract] [Full Text] [Related]

  • 52. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A, Crisà E, Lea N, Passera R, Mian S, Anwar J, Best S, Nicolini FE, Ireland R, Aldouri M, Pocock C, Corbett T, Gale R, Bart-Smith E, Weston-Smith S, Wykes C, Kulasekararaj A, Jackson S, Harrington P, McLornan D, Raj K, Pagliuca A, Mufti GJ, de Lavallade H.
    Lancet Haematol; 2019 May 06; 6(5):e276-e284. PubMed ID: 31036317
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.
    Am J Hematol; 2015 Apr 06; 90(4):282-7. PubMed ID: 25530131
    [Abstract] [Full Text] [Related]

  • 56. Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR-ABL1 transcript using Nanopore sequencing.
    Zhao H, Chen Y, Shen C, Li L, Li Q, Tan K, Huang H, Hu G.
    J Gene Med; 2021 Jan 06; 23(1):e3276. PubMed ID: 32949441
    [Abstract] [Full Text] [Related]

  • 57. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct 06; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

  • 58. Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
    Martínez-Castillo M, Gómez-Romero L, Tovar H, Olarte-Carrillo I, García-Laguna A, Barranco-Lampón G, De la Cruz-Rosas A, Martínez-Tovar A, Hernández-Zavala A, Córdova EJ.
    Leuk Res; 2023 Aug 06; 131():107325. PubMed ID: 37302352
    [Abstract] [Full Text] [Related]

  • 59. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
    Andrikovics H, Nahajevszky S, Szilvási A, Bors A, Adám E, Kozma A, Kajtár B, Barta A, Poros A, Tordai A.
    Hematol Oncol; 2007 Sep 06; 25(3):143-7. PubMed ID: 17530620
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.